Tremfya (Guselkumab) Denied: Appealing Psoriasis and PsA Coverage Denials

Tremfya (guselkumab) is a selective IL-23 inhibitor FDA-approved for moderate-to-severe plaque psoriasis and active psoriatic arthritis. As a p19 IL-23 subunit inhibitor, Tremfya offers a targeted mechanism that differs from both TNF inhibitors and IL-17 inhibitors, and it has demonstrated durable response rates with a favorable dosing schedule. Despite its evidence base and FDA approvals, Tremfya denials are frequent — often due to step therapy requirements, formulary positioning, or insufficient severity documentation.

Why Tremfya Gets Denied

Step therapy before IL-23 inhibitors. Many insurance plans tier their biologics, requiring trial and failure of a TNF inhibitor (Humira, Enbrel, Remicade) before approving a selective IL-23 inhibitor like Tremfya. This requirement is a plan-specific policy — not based on clinical evidence — and can be challenged through step therapy bypass appeals.

Formulary preference for competing agents. Some plans prefer Skyrizi (risankizumab) or Ilumya (tildrakizumab) over Tremfya, despite all three being IL-23 inhibitors. If the insurer has a preferred IL-23 agent, the denial is formulary-based, requiring a non-formulary exception documenting why Tremfya specifically is necessary for this patient.

PsA step therapy. For psoriatic arthritis, step therapy requirements typically progress through NSAIDs, then conventional DMARDs (methotrexate), then TNF inhibitors, before an IL-23 inhibitor is considered. Tremfya's PsA approval came after its psoriasis approval, and some coverage policies have not fully integrated the PsA indication — meaning the denial may simply reflect an outdated policy.

Severity criteria for psoriasis. Moderate-to-severe psoriasis is defined by PASI ≥ 12, BSA ≥ 10%, or IGA ≥ 3. Documentation using these validated measures must appear in the Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization submission and the prescriber's clinical notes.

Arguing the IL-23 Mechanism Advantage

A key component of a Tremfya appeal — especially for patients who failed TNF inhibitors — is mechanistic differentiation. Here is how to frame it:

TNF inhibitors (adalimumab, etanercept, infliximab) block tumor necrosis factor broadly. IL-23 inhibitors selectively block the p19 subunit of IL-23, which drives the Th17 inflammatory cascade responsible for the skin and joint manifestations of psoriatic disease. In patients who did not respond to TNF inhibitors or who experienced secondary loss of response, mechanistically distinct IL-23 inhibition represents a rational therapeutic step — not just a preference.

The VOYAGE 1 and VOYAGE 2 trials for Tremfya demonstrated sustained PASI 90 response rates over 100+ weeks with a Q8W maintenance dosing schedule, which reduces injection burden compared to some competitors. If your prescriber recommends Tremfya for adherence and maintenance reasons, include this in the appeal.

PsA-Specific Appeal Points

For psoriatic arthritis appeals, document the joint manifestations explicitly:

• Number of swollen and tender joints at the most recent visit
• DAS-28 or DAPSA score if recorded
• Presence of dactylitis (sausage digits) or enthesitis, which are particularly associated with PsA and are included in Tremfya's PsA trial endpoints
• Any radiographic progression (joint erosions) documented on X-ray or MRI

Tremfya's DISCOVER 1 and DISCOVER 2 trial data specifically showed inhibition of radiographic progression in PsA — a point worth including in appeals for patients with documented erosive disease.

Non-Formulary Exception Process

If Tremfya is not on your plan's formulary and the insurer's preferred IL-23 inhibitor is a different agent, the non-formulary exception process requires:

1. A prescriber letter stating the medical necessity of Tremfya specifically (not just any IL-23 inhibitor)
2. Documentation of why the preferred formulary agent is inadequate — for example, prior trial of the preferred agent with insufficient response, or clinical contraindication
3. In some cases, a clinical pharmacist or specialist supporting letter

If your prescriber has not tried you on the formulary-preferred IL-23 agent, the strongest appeal requires explaining why starting with the non-formulary agent is medically justified — typically because of clinical trial participation, established tolerability with guselkumab, or specific disease subtype.

Fight Back With ClaimBack

A Tremfya denial for psoriasis or psoriatic arthritis is often based on formulary positioning rather than clinical evidence — and that kind of denial is very winnable on appeal. ClaimBack helps you make the strongest possible case with the specific clinical and mechanistic arguments that change outcomes.

Start your Tremfya appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied